Interim futility analysis with intermediate endpoints

Clinical Trials

Volumn 5, Issue 1, 2008, Pages 14-22

  Goldman, Bryan ^a,b   LeBlanc, Michael ^a   Crowley, John ^a  

^a SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^b Southwest Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE HYPOTHESIS; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL RESEARCH; CONTROLLED STUDY; DISEASE FREE INTERVAL; HAZARD RATIO; HUMAN; INTERIM FUTILITY ANALYSIS; NULL HYPOTHESIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SIMULATION; SURVIVAL TIME;

CLINICAL TRIALS, PHASE III AS TOPIC; COMPUTER SIMULATION; DECISION MAKING; ENDPOINT DETERMINATION; HUMANS; MEDICAL FUTILITY; NEOPLASMS; RESEARCH DESIGN; SURVIVAL ANALYSIS;

EID: 40949146496     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774507086648     Document Type: Article

References (16)

1. Green SG, Benedetti J, Crowley J. Clinical Trials in Oncology (2nd edn), New York, Chapman & Hall/ CRC Press, 2003.
2. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 1971; 44: 793-797.
3. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977; 64: 191-199.
4. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-556.
5. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Control Clin Trials 1984; 5: 348-361.
6. Wang SK, Tsiatis AA. Approximately optimal one-parameter boundaries for group sequential trials. Biometrics 1987; 43: 193-199.
7. Dignam JJ, Bryant J, Wieand HS. Early stopping of cancer clinical trials. In Crowley C, Ankerst DP. (Eds). Handbook of Statistics in Clinical Oncology (2nd edn), Boca Raton, FL, CRC Press, 2006, pp. 227-246.
8. Prentice RL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 1989; 8: 431-440.
9. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992; 11: 167-178.
10. Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being misled? Ann Intern Med 1996; 125: 605-613.
11. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23: 8664-70.
12. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Nat Cancer Inst 2006; 98: 516-21.
13. Kelly K, Crowley J, Bunn PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group Trial. J Clin Oncol 2001; 19: 3210-8.
14. Lara PN, Redman MW, Kelly K, et al. Alternative measures predicting clinical benefit in advanced non-small cell lung cancer (NSCLC) from Southwest Oncology Group (SWOG) randomized trials: Implications for clinical trial design. J Clin Oncol ASCO Annual Meeting Proc Part I 2006; 24: 7006.
15. Jennison C, Turnbull BW. Group sequential tests for bivariate response: Interim analyses of clinical trials with both efficacy and safety endpoints. Biometrics 1993; 49: 741-52.
16. Freidlin B, Korn E. A comment on futility monitoring. Control Clin Trials 2002; 23: 355-366.